SG11201804758QA - Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab - Google Patents
Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumabInfo
- Publication number
- SG11201804758QA SG11201804758QA SG11201804758QA SG11201804758QA SG11201804758QA SG 11201804758Q A SG11201804758Q A SG 11201804758QA SG 11201804758Q A SG11201804758Q A SG 11201804758QA SG 11201804758Q A SG11201804758Q A SG 11201804758QA SG 11201804758Q A SG11201804758Q A SG 11201804758QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pharmaceutical formulation
- aqueous pharmaceutical
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristspi id (43) International Publication Date .... .....r ,„„01 15 June 2017(15.06.2017) WIPO I PCT ID Hit (10) WO International 2017/097407 111111111111111111IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIMIIIIIIIIIIIIIII Publication Al Number (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 39/395 (2006.01) C07K 16/28 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/EP2016/002040 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 5 December 2016 (05.12.2016) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 15198233.7 7 December 2015 (07.12.2015) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicants: MERCK PATENT GMBH [DE/DE]; Frank- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, flirter Strasse 250, 64293 Darmstadt (DE). PFIZER, INC. TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [US/US]; 235 East 42nd Street, New York, New York DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 10017 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: RINALDI, Gianluca; Via Gino Silvestrini 9, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 00015 Monterotondo (IT). DEL RIO, Alessandra; Via GW, KM, ML, MR, NE, SN, TD, TG). lldebrando Vivanti 108, 00144 Roma (IT). FRATAR- Published: CANGELI, Silvia; C.so Risorgimento 3, 03024 Ceprano with international search report (Art 21(3)) FR (IT). — with sequence listing of description (Rule 5.2(a)) part (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Il .4t IN C:: , i t IN CI P C:: , IN l'I C:: , N (54) Title: AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-1 ANTIBODY AVELUMAB 52 (57) : The present invention relates to a novel anti-PD-Ll antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15198233 | 2015-12-07 | ||
PCT/EP2016/002040 WO2017097407A1 (en) | 2015-12-07 | 2016-12-05 | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804758QA true SG11201804758QA (en) | 2018-07-30 |
Family
ID=54838201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804758QA SG11201804758QA (en) | 2015-12-07 | 2016-12-05 | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab |
Country Status (35)
Country | Link |
---|---|
US (2) | US11058769B2 (en) |
EP (2) | EP3386541B1 (en) |
JP (1) | JP6925337B2 (en) |
KR (1) | KR20180085801A (en) |
CN (1) | CN108367072B (en) |
AR (1) | AR107014A1 (en) |
AU (1) | AU2016368099C1 (en) |
BR (1) | BR112018010211A2 (en) |
CA (1) | CA3007481C (en) |
CL (1) | CL2018001488A1 (en) |
CO (1) | CO2018005525A2 (en) |
CY (1) | CY1123358T1 (en) |
DK (1) | DK3386541T3 (en) |
EA (1) | EA201891339A1 (en) |
ES (1) | ES2823279T3 (en) |
HK (1) | HK1257781A1 (en) |
HR (1) | HRP20201573T1 (en) |
HU (1) | HUE050811T2 (en) |
IL (1) | IL259563B (en) |
LT (1) | LT3386541T (en) |
MX (1) | MX2018006875A (en) |
MY (1) | MY195681A (en) |
NZ (1) | NZ743964A (en) |
PE (1) | PE20181400A1 (en) |
PH (1) | PH12018500894A1 (en) |
PL (1) | PL3386541T3 (en) |
PT (1) | PT3386541T (en) |
RS (1) | RS61029B1 (en) |
SA (1) | SA518391743B1 (en) |
SG (1) | SG11201804758QA (en) |
SI (1) | SI3386541T1 (en) |
TW (1) | TWI630917B (en) |
UA (1) | UA123270C2 (en) |
WO (1) | WO2017097407A1 (en) |
ZA (1) | ZA201804534B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2785375T (en) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
CU20170052A7 (en) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | ANTIBODY MOLECULES THAT JOIN PD-L1 |
CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
ES2823279T3 (en) | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising Avelumab anti-PD-1 antibody |
PE20190510A1 (en) | 2016-06-13 | 2019-04-10 | I Mab | ANTI-PD-L1 ANTIBODIES AND USES OF THE SAME |
JP2019530704A (en) | 2016-10-06 | 2019-10-24 | ファイザー・インコーポレイテッド | Avelumab dosing regimen for the treatment of cancer |
TW201834639A (en) * | 2017-03-06 | 2018-10-01 | 德商馬克專利公司 | Aqueous antibody formulation |
WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
CN111246886B (en) * | 2017-11-02 | 2022-03-15 | 正大天晴药业集团股份有限公司 | Pharmaceutical composition of anti-PD-L1 humanized monoclonal antibody |
WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
WO2020060183A1 (en) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | Liquid formation for stabilizing trastuzumab antibody |
KR20210096640A (en) * | 2018-11-29 | 2021-08-05 | 하버 바이오메드 테라푸틱스 리미티드 | Anti-PD-L1 Antibody Formulations |
MX2021009851A (en) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Therapeutic antibody formulation. |
US20220251210A1 (en) * | 2019-06-25 | 2022-08-11 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof |
TW202114637A (en) * | 2019-08-22 | 2021-04-16 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof |
KR20220115803A (en) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | Stable Anti-PD-1 Antibody Pharmaceutical Formulations |
KR20240043747A (en) | 2021-07-02 | 2024-04-03 | 예일 유니버시티 | Compositions and methods for treating cancer |
AU2022340804A1 (en) | 2021-08-31 | 2024-03-21 | Gennao Bio, Inc. | Compositions and methods for treating cancers |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (en) * | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
JP5209476B2 (en) | 2005-09-02 | 2013-06-12 | グリコミメティクス, インコーポレイテッド | Heterobifunctional all-selectin inhibitor |
CN101822820A (en) | 2005-12-20 | 2010-09-08 | 布里斯托尔—迈尔斯斯奎布公司 | Stable protein formulations |
US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
PE20120341A1 (en) * | 2008-12-09 | 2012-04-24 | Genentech Inc | ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
JP2013515754A (en) * | 2009-12-29 | 2013-05-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Novel antibody formulation |
US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
TR201810298T4 (en) * | 2011-03-31 | 2018-08-27 | Merck Sharp & Dohme | Stable formulations of antibodies against human programmed death receptor PD-1 and related treatments. |
LT2785375T (en) * | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
MX357393B (en) | 2012-01-23 | 2018-07-06 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies. |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
MY175472A (en) * | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
AU2014337263B2 (en) * | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
RU2695332C2 (en) * | 2014-05-15 | 2019-07-23 | Бристол-Маерс Сквибб Компани | Treating lung cancer by combination of anti-pd-1 and other anti-cancer agents |
CN105085680A (en) * | 2014-05-23 | 2015-11-25 | 复旦大学 | Humanized anti-PD-1 and c-MET bispecific antibody, and preparation method and application thereof |
CN112263677A (en) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | PD-1/PD-L1 inhibitors for the treatment of cancer |
WO2016181349A1 (en) | 2015-05-14 | 2016-11-17 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body |
US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
JP2018529719A (en) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Combination of PD-1 system binding antagonist and ALK inhibitor for treating ALK negative cancer |
ES2823279T3 (en) | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising Avelumab anti-PD-1 antibody |
TW201834639A (en) | 2017-03-06 | 2018-10-01 | 德商馬克專利公司 | Aqueous antibody formulation |
-
2016
- 2016-12-05 ES ES16818985T patent/ES2823279T3/en active Active
- 2016-12-05 UA UAA201807363A patent/UA123270C2/en unknown
- 2016-12-05 PT PT168189850T patent/PT3386541T/en unknown
- 2016-12-05 EP EP16818985.0A patent/EP3386541B1/en active Active
- 2016-12-05 EA EA201891339A patent/EA201891339A1/en unknown
- 2016-12-05 CN CN201680071740.1A patent/CN108367072B/en active Active
- 2016-12-05 MX MX2018006875A patent/MX2018006875A/en unknown
- 2016-12-05 EP EP20184113.7A patent/EP3747466A1/en not_active Withdrawn
- 2016-12-05 KR KR1020187019480A patent/KR20180085801A/en active Search and Examination
- 2016-12-05 LT LTEP16818985.0T patent/LT3386541T/en unknown
- 2016-12-05 DK DK16818985.0T patent/DK3386541T3/en active
- 2016-12-05 WO PCT/EP2016/002040 patent/WO2017097407A1/en active Application Filing
- 2016-12-05 US US16/060,319 patent/US11058769B2/en active Active
- 2016-12-05 JP JP2018529213A patent/JP6925337B2/en active Active
- 2016-12-05 MY MYPI2018702171A patent/MY195681A/en unknown
- 2016-12-05 AU AU2016368099A patent/AU2016368099C1/en active Active
- 2016-12-05 CA CA3007481A patent/CA3007481C/en active Active
- 2016-12-05 NZ NZ743964A patent/NZ743964A/en unknown
- 2016-12-05 SI SI201630940T patent/SI3386541T1/en unknown
- 2016-12-05 RS RS20201201A patent/RS61029B1/en unknown
- 2016-12-05 PL PL16818985T patent/PL3386541T3/en unknown
- 2016-12-05 PE PE2018001077A patent/PE20181400A1/en unknown
- 2016-12-05 HU HUE16818985A patent/HUE050811T2/en unknown
- 2016-12-05 BR BR112018010211A patent/BR112018010211A2/en active Search and Examination
- 2016-12-05 SG SG11201804758QA patent/SG11201804758QA/en unknown
- 2016-12-06 TW TW105140288A patent/TWI630917B/en active
- 2016-12-07 AR ARP160103760A patent/AR107014A1/en unknown
-
2018
- 2018-04-26 PH PH12018500894A patent/PH12018500894A1/en unknown
- 2018-05-23 IL IL259563A patent/IL259563B/en active IP Right Grant
- 2018-05-25 CO CONC2018/0005525A patent/CO2018005525A2/en unknown
- 2018-06-04 CL CL2018001488A patent/CL2018001488A1/en unknown
- 2018-06-06 SA SA518391743A patent/SA518391743B1/en unknown
- 2018-07-06 ZA ZA201804534A patent/ZA201804534B/en unknown
-
2019
- 2019-01-04 HK HK19100169.4A patent/HK1257781A1/en unknown
-
2020
- 2020-09-24 CY CY20201100904T patent/CY1123358T1/en unknown
- 2020-10-05 HR HRP20201573TT patent/HRP20201573T1/en unknown
- 2020-12-09 US US17/116,587 patent/US20210100903A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201811640SA (en) | Multispecific antigen binding proteins and methods of use thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201408261UA (en) | Syringe | |
SG11201408056YA (en) | Fire suppression systems, devices, and methods | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201805204WA (en) | Nicotine particle capsule | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804712PA (en) | Biofuel | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201810352XA (en) | New antibacterial compounds | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
SG11201408171SA (en) | Fbxo3 inhibitors | |
SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
SG11201900043TA (en) | Antibody formulations |